Your browser is no longer supported. Please, upgrade your browser.
APLS Apellis Pharmaceuticals, Inc. daily Stock Chart
Apellis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.61 Insider Own2.40% Shs Outstand75.55M Perf Week-7.40%
Market Cap2.52B Forward P/E- EPS next Y-6.42 Insider Trans-2.36% Shs Float59.10M Perf Month2.02%
Income-470.50M PEG- EPS next Q-1.57 Inst Own82.60% Short Float18.44% Perf Quarter11.95%
Sales- P/S- EPS this Y-108.90% Inst Trans0.06% Short Ratio17.74 Perf Half Y-7.58%
Book/sh3.07 P/B10.68 EPS next Y9.30% ROA-77.90% Target Price51.62 Perf Year17.39%
Cash/sh10.84 P/C3.03 EPS next 5Y2.80% ROE-283.10% 52W Range16.85 - 45.04 Perf YTD7.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.31% Beta-
Dividend %- Quick Ratio14.70 Sales past 5Y- Gross Margin- 52W Low99.64% ATR1.70
Employees235 Current Ratio14.70 Sales Q/Q- Oper. Margin- RSI (14)53.34 Volatility4.87% 5.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-39.70% Profit Margin- Rel Volume0.43 Prev Close32.80
ShortableYes LT Debt/Eq1.50 Earnings- Payout- Avg Volume614.10K Price33.64
Recom1.80 SMA201.89% SMA508.13% SMA2003.24% Volume173,385 Change2.56%
Sep-01-20Initiated Stifel Buy $40
Jul-20-20Initiated ROTH Capital Buy $50
Jun-17-20Initiated BTIG Research Neutral
Apr-01-20Initiated Raymond James Strong Buy $86
Mar-31-20Initiated BMO Capital Markets Outperform $54
Mar-11-20Upgrade Wedbush Underperform → Neutral $29
Jan-07-20Initiated SVB Leerink Mkt Perform $30
Dec-19-19Initiated BofA/Merrill Buy $36
Nov-22-19Initiated Wedbush Underperform
Nov-05-19Initiated Credit Suisse Neutral $33
Aug-01-19Reiterated Cantor Fitzgerald Overweight $52 → $50
Jul-12-19Upgrade JP Morgan Neutral → Overweight $35 → $49
Mar-29-19Initiated Robert W. Baird Outperform $45
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Jul-30-18Upgrade B. Riley FBR Neutral → Buy $27
May-24-18Initiated Cantor Fitzgerald Overweight $52
Apr-12-18Downgrade B. Riley FBR, Inc. Buy → Neutral $27
Feb-08-18Initiated B. Riley FBR, Inc. Buy $27
Oct-19-20 07:00AM  
Oct-15-20 07:00AM  
Oct-09-20 10:14AM  
Oct-07-20 04:05PM  
Oct-05-20 07:00AM  
Oct-03-20 11:05AM  
Sep-24-20 04:05PM  
Sep-21-20 04:05PM  
Sep-16-20 03:25PM  
Sep-15-20 07:00AM  
Sep-04-20 04:05PM  
Sep-02-20 07:00AM  
Sep-01-20 09:47AM  
Aug-30-20 11:30AM  
Aug-21-20 04:05PM  
Aug-07-20 04:05PM  
Jul-31-20 07:00AM  
Jul-13-20 10:31AM  
Jul-07-20 04:05PM  
Jul-02-20 08:00AM  
Jun-16-20 07:00AM  
Jun-12-20 04:23PM  
Jun-10-20 05:34PM  
Jun-05-20 04:05PM  
Jun-04-20 07:00AM  
May-29-20 04:05PM  
May-28-20 07:00AM  
May-21-20 07:00AM  
May-14-20 10:55AM  
May-08-20 07:00AM  
May-07-20 04:05PM  
Apr-29-20 04:11PM  
Apr-28-20 07:00AM  
Apr-07-20 11:33AM  
Apr-06-20 08:00AM  
Feb-27-20 04:44PM  
Feb-26-20 07:00AM  
Feb-06-20 01:23PM  
Jan-16-20 04:30PM  
Jan-15-20 05:39AM  
Jan-13-20 04:57PM  
Jan-09-20 02:18PM  
Jan-08-20 09:30PM  
Jan-07-20 04:15PM  
Jan-02-20 07:00AM  
Dec-09-19 08:48AM  
Dec-06-19 04:11PM  
Nov-26-19 07:00AM  
Nov-15-19 05:30PM  
Nov-08-19 10:00AM  
Nov-07-19 05:30PM  
Nov-05-19 07:30AM  
Oct-28-19 09:26AM  
Oct-16-19 11:43AM  
Oct-11-19 04:01PM  
Oct-04-19 05:30PM  
Oct-03-19 08:37AM  
Sep-27-19 05:30PM  
Sep-26-19 08:00AM  
Sep-18-19 08:00AM  
Sep-16-19 05:00PM  
Sep-13-19 07:31AM  
Sep-12-19 08:22AM  
Sep-11-19 04:38PM  
Sep-09-19 05:00PM  
Sep-03-19 08:00AM  
Aug-28-19 05:00PM  
Aug-25-19 11:31AM  
Aug-16-19 05:00PM  
Aug-02-19 06:00AM  
Jul-31-19 05:00PM  
Jul-26-19 05:30PM  
Jul-22-19 02:34PM  
Jul-18-19 07:00AM  
Jul-14-19 07:03PM  
Jul-12-19 09:42AM  
Jul-08-19 05:30PM  
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Machiels AlecDirectorOct 15Option Exercise2.672,5006,675672,044Oct 16 05:56 PM
Francois CedricChief Executive OfficerOct 15Sale34.465,000172,3001,083,079Oct 16 05:31 PM
Machiels AlecDirectorOct 15Sale35.002,50087,500669,544Oct 16 05:56 PM
Brown Victoria L.Program Team LeadOct 07Option Exercise18.9812,000227,76015,607Oct 09 04:45 PM
Machiels AlecDirectorOct 07Option Exercise2.677,50020,025677,044Oct 09 04:48 PM
Brown Victoria L.Program Team LeadOct 07Sale35.0012,000420,0003,607Oct 09 04:45 PM
Machiels AlecDirectorOct 07Sale35.007,500262,500669,544Oct 09 04:48 PM
Grossi FedericoSee RemarksOct 01Sale30.2260018,13228,325Oct 02 04:14 PM
Francois CedricChief Executive OfficerSep 15Sale30.965,000154,8001,088,079Sep 16 04:03 PM
Grossi FedericoSee RemarksSep 01Sale31.5860018,94828,925Sep 02 04:36 PM
Francois CedricChief Executive OfficerAug 20Sale30.003,457103,7101,093,079Aug 21 04:36 PM
Francois CedricChief Executive OfficerAug 18Sale30.001,54346,2901,096,536Aug 20 04:45 PM
Grossi FedericoSee RemarksAug 03Sale26.2860015,76829,525Aug 05 04:37 PM
Francois CedricChief Executive OfficerJul 15Sale32.125,000160,6001,098,079Jul 16 04:07 PM
Grossi FedericoSee RemarksJul 01Sale32.4385027,56630,125Jul 02 05:48 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.